FibroGen (NASDAQ:FGEN) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of FibroGen (NASDAQ:FGEN) in a research note issued to investors on Friday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

A number of other equities research analysts have also issued reports on FGEN. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research note on Thursday. William Blair restated a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Stock Performance

FGEN stock opened at $0.71 on Friday. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.80. The firm has a market cap of $71.13 million, a P/E ratio of -0.57 and a beta of 0.75. The stock has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $0.43.

Institutional Investors Weigh In On FibroGen

A number of hedge funds have recently bought and sold shares of FGEN. Assenagon Asset Management S.A. acquired a new stake in FibroGen during the 3rd quarter valued at approximately $307,000. FMR LLC grew its position in shares of FibroGen by 21.8% in the 3rd quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares in the last quarter. Geode Capital Management LLC grew its position in shares of FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock worth $433,000 after acquiring an additional 32,884 shares in the last quarter. JPMorgan Chase & Co. grew its position in shares of FibroGen by 430.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares in the last quarter. Finally, Franklin Street Advisors Inc. NC grew its position in shares of FibroGen by 100.0% in the 4th quarter. Franklin Street Advisors Inc. NC now owns 200,000 shares of the biopharmaceutical company’s stock worth $106,000 after acquiring an additional 100,000 shares in the last quarter. Institutional investors and hedge funds own 72.71% of the company’s stock.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.